Portal de recerca
ESTUDIO DE SEGUIMIENTO DE LA EFICACIA Y SEGURIDAD DE KOGENATE BAYER.
Dades bàsiques
- Protocol:
- KG0201
- EURDRACT:
- NO PROCEDE
- NCT:
- Centre:
- Any inici:
- Any de finalització:
Documents
- No hi ha documents
Participants
Grups d'Investigació
Finançadors - Promotors
Resultats de l'Assaig Clínic
Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2021.07.009. 2021
Development and testing of a mobile app for systematic collection of patient-reported outcomes (PROs) in patients with hemophilia.
Megias-Vericat, J E; (...); Poveda Andres, J L
Letter. 10.1016/j.thromres.2024.109122. 2024
Efficacy and safety evaluation of Fanhdi ® , a plasma-derived factor VIII/ von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study.
Jimenez-Yuste, Victor; (...); Paez, Antonio
Letter. 10.1111/hae.14453. 2022
Emicizumab-induced photosensitivity.
Asensi Canto, Pedro; (...); Haya Guaita, Saturnino
Article. 10.1055/s-0042-1749092. 2022
Haemotrack: Musculoskeletal management in haemophilia with physiotherapist-driven digital solutions
Perez-Alenda, Sofia; (...); Aguilar-Rodriguez, Marta
Meeting Abstract. 2024
Management of acquired hemophilia A: results from the Spanish registry.
Mingot-Castellano ME; (...); Marco P
Article. 10.1182/bloodadvances.2021004626. 2021
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products.
Megias-Vericat, J. E.; (...); Poveda Andres, J. L.
Article. 10.1016/j.thromres.2022.06.001. 2022
Real-world analysis of the PK-guided switch from standard half-life factor VIII to efmoroctocog alfa.
Megias-Vericata, J. E.; (...); Poveda Andres, J L
Letter. 10.1016/j.thromres.2023.11.023. 2023